Dergiler / Gülhane Tıp Dergisi / 2018 / Cilt: 60 - Sayı: 2

Gene correction applications in cell replacement therapy and use in neurodegenerative diseases

Sayfa
60–63
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

It seems that, these advanced technologies will be applied widely in permanent therapy of neurodegenerative diseases in recent future.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Induced pluripotent stem cells offer opportunities for personalized cell replacement therapy due to unlimited self renewal potential and ability to differentiate into different somatic cells.
📊
Temel Bulgular & Veri:Since 90s, a lot of new technologies have been evolved in molecular biology and genetics.
💡
Sonuç & Katkı:It seems that, these advanced technologies will be applied widely in permanent therapy of neurodegenerative diseases in recent future.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Induced pluripotent stem cells offer opportunities for personalized cell replacement therapy due to unlimited self renewal potential and ability to differentiate into different somatic cells. Autologous cell replacement therapy gives opportunity for therapeutic applications with uses of induced pluripotent stem cell technology. As known autologous induced pluripotent stem cells are genetically identical to donor cells. Therefore these cells and their cellular derivatives are not expected to be immunologically rejected. Since 90s, a lot of new technologies have been evolved in molecular biology and genetics. By using these technologies, so many genetic variations have been identified which significantly increase the risks and causes of neurodegenerative diseases in patients. An induced pluripotent stem cell obtained from a fully differentiated cell of a patient carries same mutations in genome which causes disease. Unfortunately, these mutations reduce the dedifferentiation ratio in obtaining induced pluripotent stem cells in laboratory conditions. Also, these mutations affect on induced pluripotent stem cell viability and growth. So, gene correction studies are needed before induced pluripotent stem cell technology for having optimal results in cell replacement therapy. Here in this review, new approaches in gene correction studies including homologous recombination technique were mentioned. The role of direct transdifferentiation technique was explained in obtaining a cell which can be used in replacement therapy successfully. New cell replacement therapy applications were defined especially in neurodegenerative diseases. It seems that, these advanced technologies will be applied widely in permanent therapy of neurodegenerative diseases in recent future.

🔖

Bu Makaleye Atıf Yap

GÜRAN, Ş. (2018). Gene correction applications in cell replacement therapy and use in neurodegenerative diseases. Gülhane Tıp Dergisi, Cilt: 60 - Sayı: 2, 60–63. https://ajindex.com/articles/165008

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (10)

  1. Yamanaka S. Induced pluripotent stem cells: past, present, and future. Cell Stem Cell 2012; 10(6): 678–684.
  2. Güran S, Coban ZD. The Use of Induced Pluripotent Stem Cells in Medicine. Erciyes Med J 2012; 34(4): 184- 187. Deng H, Wang P, Jankovic J. The genetics of Parkinson disease. Ageing Res Rev. 2017; 42(3): 72-85. Błaszczyk JW. Nigrostriatal interaction in the aging brain: new therapeutic target for Parkinson’s disease. Acta Neurobiol Exp (Wars). 2017; 77(1): 106-112.
  3. Lee G, Studer L. Induced pluripotent stem cell technology for the study of human disease. Nat Methods. 2010; 7(1): 25-7.
  4. Park IH, Arora N, Huo H, et al. Disease-specific induced pluripotent stem cells. Cell, 2018; 134 (5): 877–886.
  5. Correia AS, Anisimov SV, Li JY, Brundin P. Stem cellbased therapy for Parkinson’s disease. Ann Med. 2005;37(7):487-498. Poulos J. The limited application of stem cells in medicine: a review. Stem Cell Res Ther. 2018; 9(1): 1. Lyreskog DM. Frailty and Neurodegenerative Disease: Anticipating the Future, Expanding the Framework. J Frailty Aging. 2018; 7(1): 57-59. Cully M. Neurodegenerative diseases: Inflammasome protein seeds plaques in Alzheimer disease. Nat Rev Drug Discov. 2018 Feb 1;17(2):96. Jiang P, Dickson DW. Parkinson’s disease: experimental models and reality. Acta Neuropathol. 2018; 135(1): 13- 32. Brändl B, Schneider SA, Loring JF, Hardy J, Gribbon P, Müller FJ. Stem cell reprogramming: basic implications and future perspective for movement disorders. Mov Disord. 2015; 30(3): 301-312.
  6. Zhu B, Caldwell M, Song B. Development of stem cellbased therapies for Parkinson’s disease. Int J Neurosci. 2016; 126(11): 955-962.
  7. Leavitt AD, Hamlett I. Homologous recombination in human embryonic stem cells: a tool for advancing cell therapy and understanding and treating human disease. Clin Transl Sci. 2011; 4(4): 298-305.
  8. Jang YY, Ye Z. Gene correction in patient-specific iPSCs for therapy development and disease modeling. Hum Genet. 2016; 135(9): 1041-1058.
  9. Recasens A, Dehay B, Bové J, Carballo-Carbajal I, et al. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol. 2014; 75(3): 351-362.
  10. Bonilla-Porras AR, Arevalo-Arbelaez A, Alzate-Restrepo JF, Velez-Pardo C, Jimenez-Del-Rio M. PARKIN overexpression in human mesenchymal stromal cells from Wharton’s jelly suppresses 6-hydroxydopamine-induced apoptosis: Potential therapeutic strategy in Parkinson’s disease. Cytotherapy. 2018; 20(1): 45-61.